HeartBeam Inc Receives FDA Clearance for 12-Lead ECG Software
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 16 2025
0mins
Should l Buy BEAT?
HeartBeam Inc's stock surged by 16.13%, reaching a 5-day high, amid a broader market decline with the Nasdaq-100 down 0.77% and the S&P 500 down 0.29%.
This increase is attributed to HeartBeam receiving FDA 510(k) clearance for its innovative 12-lead ECG synthesis software, a significant breakthrough in cardiac care that allows patients to assess arrhythmias from home. The company plans a limited U.S. commercial launch in early 2026, targeting partnerships with cardiology practices, which is expected to enhance market penetration and growth opportunities.
The FDA clearance positions HeartBeam to capitalize on the growing demand for at-home cardiac monitoring solutions, potentially reshaping the future of cardiac health management and expanding its market share.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BEAT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BEAT
Wall Street analysts forecast BEAT stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.920
Low
4.00
Averages
5.83
High
8.00
Current: 0.920
Low
4.00
Averages
5.83
High
8.00
About BEAT
HeartBeam, Inc. is a cardiac technology company. The Company focuses on developing and commercializing higher resolution ambulatory Electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease both inside and outside a healthcare facility setting. It is engaged in the development of higher resolution ECG solutions is achieved through the development of the Company’s proprietary and patented electrocardiography technology platform. It is developing three-dimensional (3D) representations of cardiac electrical activity by displaying the spatial locations of ECG waveforms. It is developing its own product, the HeartBeam System. The HeartBeam System comprises a credit card sized 12-lead output electrocardiogram device, a patient application, a physician portal, and powerful cloud-based algorithms. The core technology consists of a series of patented inventions that allow it to capture the heart’s electrical activity from three distinct directions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
HeartBeam Prices Public Offering to Raise $10 Million
- Offering Size: HeartBeam priced its public offering at $0.80 per share for a total of 12.5 million shares, aiming to raise $10 million, which indicates the company's ability to access capital markets but also reflects investor concerns about its stock price.
- Underwriter Option: The underwriters have a 30-day option to purchase an additional 1.875 million shares, providing flexibility that could offer further funding support while potentially impacting market liquidity expectations for the stock.
- Use of Proceeds: The net proceeds will fund the commercialization of its FDA-cleared 12-lead synthesized ECG system, development of an extended-wear patch, and AI enhancements for heart attack detection tools, highlighting the company's strategic focus on innovation in cardiac health.
- Stock Price Movement: Following the offering announcement, HeartBeam's stock price declined approximately 12% in after-hours trading on Tuesday, reflecting cautious investor sentiment regarding the company's future prospects, which may affect its subsequent financing and market confidence.
See More
HeartBeam Initiates Underwritten Public Offering of Common Stock
- Offering Launch: HeartBeam announced the commencement of an underwritten public offering of its common stock, with all shares being issued and sold by the company, indicating a proactive approach to financing amid market conditions.
- Clear Use of Proceeds: The net proceeds from this offering will be utilized to launch and grow its FDA-approved ECG system, develop an extended-wear patch, support heart attack detection initiatives, and enhance AI capabilities, demonstrating the company's commitment to technological innovation.
- Market Reaction: Despite HeartBeam closing flat at $1.20 during regular trading, it fell to $0.98 in after-hours trading, down approximately 18.33%, reflecting a cautious market sentiment regarding the financing initiative.
- Underwriter Selection: Titan Partners has been appointed as the sole bookrunner for the offering, showcasing the company's strategic considerations in partner selection to ensure a smooth financing process.
See More
Heart Disease Crisis Fuels AI Diagnostic Platforms
- Economic Burden of Heart Disease: Heart disease costs the European Union over €282 billion annually and claims 1.7 million lives, driving institutional capital to rapidly invest in scalable AI diagnostic platforms, highlighting the urgent market demand for innovative healthcare solutions.
- Growth of AI Medical Devices: The FDA has approved over 1,200 AI medical devices, with cardiovascular applications emerging as the second largest category, indicating a strong alignment between regulatory support and clinical needs, providing a favorable environment for AI-driven medical technologies.
- Remote Healthcare Collaboration: VentriPoint Diagnostics is partnering with First Light Health to deliver AI cardiac diagnostics in remote Canadian communities, utilizing the VMS+™ system to enable local providers to collaborate with central specialists, significantly enhancing healthcare accessibility in underserved areas.
- Potential for Technological Expansion: VentriPoint's VMS+™ system converts standard 2D echocardiograms into 3D volumetric images with accuracy comparable to cardiac MRI, which is expected to drive widespread adoption in underserved communities globally, addressing critical gaps in heart disease diagnosis.
See More
Heart Disease Crisis Fuels AI Diagnostic Platforms
- Economic Burden of Heart Disease: Heart disease costs the European Union over €282 billion annually and claims 1.7 million lives each year, driving institutional capital towards scalable AI diagnostic platforms, highlighting the urgent market demand for innovative healthcare solutions.
- Growth in AI Medical Device Registrations: The FDA has approved over 1,200 AI medical devices, with cardiovascular applications emerging as the second-largest category, providing a robust regulatory foundation that supports the rapid growth of companies in this sector.
- Remote Healthcare Collaboration: VentriPoint Diagnostics has partnered with First Light Health to deliver AI-powered cardiac diagnostics to Indigenous and remote communities in Canada, utilizing the VMS+™ system to enhance accessibility and efficiency in healthcare delivery.
- Technological Innovation and Market Expansion: VentriPoint's VMS+™ system converts standard 2D echocardiograms into 3D volumetric images with MRI-level accuracy at a lower cost, positioning the company to expand into underserved global communities and address significant gaps in heart disease diagnosis.
See More
HeartBeam Q4 2025 Financial Report Analysis
- R&D Spending Increase: Research and development expenses for Q4 2025 reached $3.4 million, a 17.2% increase from $2.9 million in Q4 2024, indicating the company's ongoing commitment to technological innovation, although this may heighten short-term financial pressures.
- Widening Net Loss: The net loss for Q4 2025 was $5.3 million, up from a net loss of $4.9 million in Q4 2024, reflecting high costs associated with expansion and R&D, which could impact investor confidence.
- Improved Cash Position: As of December 31, 2025, cash and cash equivalents totaled $4.4 million, an 83.3% increase from $2.4 million at the end of 2024, indicating better cash management and enhancing operational flexibility for future endeavors.
- Strategic Collaboration Outlook: HeartBeam's strategic AI collaboration with Mount Sinai may drive technological advancements and market competitiveness; despite current financial challenges, this partnership could lay the groundwork for future growth.
See More
HeartBeam Partners with Mount Sinai for AI Heart Monitoring
- Strategic Collaboration: HeartBeam has announced a strategic partnership with the Icahn School of Medicine at Mount Sinai to accelerate the development of AI-enabled heart monitoring technology, which is expected to drive innovation in cardiac health management.
- Integration of Technical Expertise: This partnership combines Mount Sinai's clinical and AI expertise with HeartBeam's patented 3D electrocardiogram platform, enabling the collection of 12-lead ECG data anytime and anywhere, thus expanding the applications of heart monitoring.
- AI Algorithm Development: By pairing high-fidelity ECG data with clinically annotated datasets, the collaboration aims to create advanced AI algorithms capable of assessing heart health trends earlier, detecting risks, and guiding more precise care.
- Market Potential Enhancement: This collaboration positions HeartBeam to move beyond rhythm monitoring into AI-enabled disease assessment and management, potentially unlocking new opportunities in preventive cardiology, chronic disease management, and remote patient monitoring.
See More
HeartBeam Prices Public Offering to Raise $10 Million
- Offering Size: HeartBeam priced its public offering at $0.80 per share for a total of 12.5 million shares, aiming to raise $10 million, which indicates the company's ability to access capital markets but also reflects investor concerns about its stock price.
- Underwriter Option: The underwriters have a 30-day option to purchase an additional 1.875 million shares, providing flexibility that could offer further funding support while potentially impacting market liquidity expectations for the stock.
- Use of Proceeds: The net proceeds will fund the commercialization of its FDA-cleared 12-lead synthesized ECG system, development of an extended-wear patch, and AI enhancements for heart attack detection tools, highlighting the company's strategic focus on innovation in cardiac health.
- Stock Price Movement: Following the offering announcement, HeartBeam's stock price declined approximately 12% in after-hours trading on Tuesday, reflecting cautious investor sentiment regarding the company's future prospects, which may affect its subsequent financing and market confidence.
See More
HeartBeam Initiates Underwritten Public Offering of Common Stock
- Offering Launch: HeartBeam announced the commencement of an underwritten public offering of its common stock, with all shares being issued and sold by the company, indicating a proactive approach to financing amid market conditions.
- Clear Use of Proceeds: The net proceeds from this offering will be utilized to launch and grow its FDA-approved ECG system, develop an extended-wear patch, support heart attack detection initiatives, and enhance AI capabilities, demonstrating the company's commitment to technological innovation.
- Market Reaction: Despite HeartBeam closing flat at $1.20 during regular trading, it fell to $0.98 in after-hours trading, down approximately 18.33%, reflecting a cautious market sentiment regarding the financing initiative.
- Underwriter Selection: Titan Partners has been appointed as the sole bookrunner for the offering, showcasing the company's strategic considerations in partner selection to ensure a smooth financing process.
See More
Heart Disease Crisis Fuels AI Diagnostic Platforms
- Economic Burden of Heart Disease: Heart disease costs the European Union over €282 billion annually and claims 1.7 million lives, driving institutional capital to rapidly invest in scalable AI diagnostic platforms, highlighting the urgent market demand for innovative healthcare solutions.
- Growth of AI Medical Devices: The FDA has approved over 1,200 AI medical devices, with cardiovascular applications emerging as the second largest category, indicating a strong alignment between regulatory support and clinical needs, providing a favorable environment for AI-driven medical technologies.
- Remote Healthcare Collaboration: VentriPoint Diagnostics is partnering with First Light Health to deliver AI cardiac diagnostics in remote Canadian communities, utilizing the VMS+™ system to enable local providers to collaborate with central specialists, significantly enhancing healthcare accessibility in underserved areas.
- Potential for Technological Expansion: VentriPoint's VMS+™ system converts standard 2D echocardiograms into 3D volumetric images with accuracy comparable to cardiac MRI, which is expected to drive widespread adoption in underserved communities globally, addressing critical gaps in heart disease diagnosis.
See More
Heart Disease Crisis Fuels AI Diagnostic Platforms
- Economic Burden of Heart Disease: Heart disease costs the European Union over €282 billion annually and claims 1.7 million lives each year, driving institutional capital towards scalable AI diagnostic platforms, highlighting the urgent market demand for innovative healthcare solutions.
- Growth in AI Medical Device Registrations: The FDA has approved over 1,200 AI medical devices, with cardiovascular applications emerging as the second-largest category, providing a robust regulatory foundation that supports the rapid growth of companies in this sector.
- Remote Healthcare Collaboration: VentriPoint Diagnostics has partnered with First Light Health to deliver AI-powered cardiac diagnostics to Indigenous and remote communities in Canada, utilizing the VMS+™ system to enhance accessibility and efficiency in healthcare delivery.
- Technological Innovation and Market Expansion: VentriPoint's VMS+™ system converts standard 2D echocardiograms into 3D volumetric images with MRI-level accuracy at a lower cost, positioning the company to expand into underserved global communities and address significant gaps in heart disease diagnosis.
See More
HeartBeam Q4 2025 Financial Report Analysis
- R&D Spending Increase: Research and development expenses for Q4 2025 reached $3.4 million, a 17.2% increase from $2.9 million in Q4 2024, indicating the company's ongoing commitment to technological innovation, although this may heighten short-term financial pressures.
- Widening Net Loss: The net loss for Q4 2025 was $5.3 million, up from a net loss of $4.9 million in Q4 2024, reflecting high costs associated with expansion and R&D, which could impact investor confidence.
- Improved Cash Position: As of December 31, 2025, cash and cash equivalents totaled $4.4 million, an 83.3% increase from $2.4 million at the end of 2024, indicating better cash management and enhancing operational flexibility for future endeavors.
- Strategic Collaboration Outlook: HeartBeam's strategic AI collaboration with Mount Sinai may drive technological advancements and market competitiveness; despite current financial challenges, this partnership could lay the groundwork for future growth.
See More
HeartBeam Partners with Mount Sinai for AI Heart Monitoring
- Strategic Collaboration: HeartBeam has announced a strategic partnership with the Icahn School of Medicine at Mount Sinai to accelerate the development of AI-enabled heart monitoring technology, which is expected to drive innovation in cardiac health management.
- Integration of Technical Expertise: This partnership combines Mount Sinai's clinical and AI expertise with HeartBeam's patented 3D electrocardiogram platform, enabling the collection of 12-lead ECG data anytime and anywhere, thus expanding the applications of heart monitoring.
- AI Algorithm Development: By pairing high-fidelity ECG data with clinically annotated datasets, the collaboration aims to create advanced AI algorithms capable of assessing heart health trends earlier, detecting risks, and guiding more precise care.
- Market Potential Enhancement: This collaboration positions HeartBeam to move beyond rhythm monitoring into AI-enabled disease assessment and management, potentially unlocking new opportunities in preventive cardiology, chronic disease management, and remote patient monitoring.
See More
